CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies
PharmTech
JUNE 12, 2025
billion and an additional $2 billion in non-contingent anniversary payments through 2028. billion (1). billion (1). This news comes just 10 days after BioNTech announced a global co-development and co-commercialization agreement valued at up to $11.1 billion for BNT327 (2). BioNTech is also eligible to receive up to $7.6 References 1.
52 
Let's personalize your content